Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $14.3B | $-395M | $-3.5B | $1.9B | -23.9% | -3.0% | 454.2% |
| 2024 | $14.7B | $2.8B | $-634M | $1.9B | -3.4% | -4.5% | -1259.4% |
| 2023 | $15.4B | $3.5B | $55M | $2.3B | 0.3% | -5.1% | -97.4% |
| 2022 | $16.3B | $6.4B | $2.1B | $2.5B | 9.9% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 14,299.90 |
| Operating Revenue | 23,732.90 |
| Cost Of Revenue | 9,286.40 |
| Gross Profit | 5,013.50 |
| Operating Expense | 4,760 |
| Research And Development | 965.90 |
| Selling General And Administration | 3,794.10 |
| Total Expenses | 14,046.40 |
| Operating Income | 253.50 |
| Total Operating Income As Reported | -2,663.10 |
| EBITDA | -395.40 |
| Normalized EBITDA | 2,521.20 |
| EBIT | -3,193.70 |
| Interest Expense | 471.30 |
| Net Interest Income | -471.30 |
| Other Non Operating Income Expenses | -530.60 |
| Other Income Expense | -3,447.20 |
| Interest Expense Non Operating | 471.30 |
| Net Non Operating Interest Income Expense | -471.30 |
| Pretax Income | -3,665 |
| Tax Provision | -150.10 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -119.58 |
| Net Income Continuous Operations | -3,514.90 |
| Net Income From Continuing And Discontinued Operation | -3,514.90 |
| Net Income From Continuing Operation Net Minority Interest | -3,514.90 |
| Net Income | -3,514.90 |
| Net Income Common Stockholders | -3,514.90 |
| Net Income Including Noncontrolling Interests | -3,514.90 |
| Normalized Income | -717.88 |
| Diluted NI Availto Com Stockholders | -3,514.90 |
| Basic Average Shares | 1,170.70 |
| Diluted Average Shares | 1,170.70 |
| Reconciled Depreciation | 2,798.30 |
| Reconciled Cost Of Revenue | 9,286.40 |
| Total Unusual Items | -2,916.60 |
| Total Unusual Items Excluding Goodwill | -2,916.60 |
| Special Income Charges | -2,916.60 |
| Other Special Charges | 131.20 |
| Impairment Of Capital Assets | 2,936.80 |
| Restructuring And Mergern Acquisition | -151.40 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Viatris Inc.this co. | VTRS | $18.5B | - | 1.26 | -23.9% | - |
| Insmed Incorporated | INSM | $22.7B | -17.81 | 30.77 | -172.8% | - |
| West Pharmaceutical Services, Inc. | WST | $22.4B | 45.41 | 7.06 | 15.5% | 28.40 |
| Quest Diagnostics Incorporated | DGX | $21.7B | 21.88 | 3.03 | 13.8% | 12.88 |
| Labcorp Holdings Inc. | LH | $21.4B | 24.41 |
| - |
| - |
| - |
| - |
| 2.48 |
| 10.2% |
| 13.61 |
| STERIS plc | STE | $20.7B | 26.48 | 2.88 | 10.9% | 14.02 |
| Moderna, Inc. | MRNA | $20.5B | -7.25 | 2.37 | -32.6% | -7.54 |
| Incyte Corporation | INCY | $20.2B | 15.72 | 3.91 | 24.9% | 9.75 |
| Zimmer Biomet Holdings, Inc. | ZBH | $16.8B | 23.79 | 1.32 | 5.6% | 10.69 |
| Peer Median | - | 22.84 | 2.96 | 10.5% | 12.88 | |